Level 1 — Absolute Beginner

Alzheimer's disease is a sickness that hurts memory and thinking. It mostly happens to older people.

Scientists in the United States found a new blood test. The test looks for tiny things in blood called circular RNAs.

The new test is better than the old test. It can also tell doctors about Alzheimer's disease two to four years before a person shows any signs.

A company named Circular Genomics wants to make this test for doctors to use. It will be called CircPATH.

disease

a sickness that harms the body or mind

memory

the ability to remember things

blood

the red liquid inside our bodies

test

a way to check something

tiny

very, very small

scientist

a person who studies the world to learn new things

doctor

a person who helps sick people get better

sign

something that shows a problem is starting

Level 2 — Elementary

Alzheimer's disease slowly damages a person's memory and thinking skills. It usually affects older adults, and doctors have long wanted a simple way to find it early, before symptoms appear.

Researchers announced by the US National Institutes of Health, in a study led by Bridget Phillips, found 34 circular RNAs, which are small molecules found in blood, that can predict whether a person will develop Alzheimer's symptoms.

The scientists tested their findings on three separate groups of patients, including two groups from the Knight Alzheimer's Disease Research Center and one group from the A4 study. The new blood test worked better than the current leading blood test, called pTau217, at detecting Alzheimer's disease and at predicting who would get symptoms within five years.

The levels of these 34 circular RNAs begin to change about two to four years before a person's memory and thinking start to decline. A company called Circular Genomics is now turning this discovery into a commercial test named CircPATH.

molecule

a very small unit made of atoms, too small to see

predict

to say what will happen before it happens

symptom

a sign in the body that shows a disease is present

researcher

a person who studies a subject to find new facts

detect

to notice or discover that something is present

patient

a person who is being treated by a doctor

decline

to become worse over time

commercial

made to be sold to the public

Level 3 — Intermediate

A study announced by the US National Institutes of Health and published in the journal Nature Medicine has identified 34 circular RNAs, small looping molecules found in blood, that can forecast a person's progression toward symptomatic Alzheimer's disease. The research, led by Bridget Phillips and colleagues, offers a potential new tool for catching the disease long before memory loss becomes noticeable.

To confirm their findings held up beyond a single dataset, the researchers validated the circRNA biomarkers across three independent patient cohorts: two from the Knight Alzheimer's Disease Research Center and one from the A4 study. Across all three groups, the new blood test consistently outperformed pTau217, the leading existing blood biomarker for Alzheimer's disease.

The improvements were substantial. For detecting confirmed Alzheimer's disease, the circRNA test achieved an AUC, a measure of test accuracy where 1.0 is perfect, of 0.945, compared with 0.877 for pTau217. For predicting the transition from normal cognition to symptomatic mild cognitive impairment or Alzheimer's, the circRNA test posted a hazard ratio of 2.92 versus 1.81 for pTau217, roughly 61 percent stronger. For forecasting who would develop symptoms within five years, the circRNA test scored an AUC of 0.870 against 0.676 for pTau217, about 29 percent stronger.

Perhaps most notable is the timing: levels of the 34 circRNAs begin shifting roughly two to four years before cognitive symptoms emerge, opening a window in which doctors could intervene earlier. A company called Circular Genomics is now developing the discovery into a commercial diagnostic platform, CircPATH, aiming to bring the biomarker panel into clinical use.

circular RNA

a looped molecule made of genetic material, found circulating in blood

biomarker

a measurable substance in the body that indicates disease or a biological state

cohort

a group of people studied together over time in research

validate

to confirm that a result is accurate by testing it independently

AUC (area under the curve)

a statistic measuring how accurately a test distinguishes between groups, with 1.0 being perfect

hazard ratio

a number comparing how likely an event is to occur in one group versus another over time

cognitive

relating to thinking, memory and understanding

clinical

relating to the direct treatment and observation of patients

Level 4 — Advanced

A study announced by the US National Institutes of Health and published in Nature Medicine, led by Bridget Phillips and colleagues, has identified a panel of 34 circulating circular RNAs, small covalently closed loop transcripts detectable in blood, that forecast an individual's trajectory toward symptomatic Alzheimer's disease with markedly greater precision than the field's current leading blood biomarker.

The panel's robustness rests on its validation across three independent cohorts, two drawn from the Knight Alzheimer's Disease Research Center and a third from the A4 study, a design intended to guard against the overfitting that can plague single-cohort biomarker discovery. Across all three, the circRNA panel consistently surpassed pTau217, phosphorylated tau at threonine 217, the plasma biomarker most widely used in current Alzheimer's research and increasingly in clinical practice.

Quantitatively, the gains were substantial across every endpoint examined. For discriminating confirmed Alzheimer's disease from unaffected individuals, the circRNA panel returned an AUC of 0.945 against 0.877 for pTau217. For modeling the hazard of converting from cognitively normal status to symptomatic mild cognitive impairment or Alzheimer's disease, the circRNA panel yielded a hazard ratio of 2.92, versus 1.81 for pTau217, an improvement of roughly 61 percent. For five-year symptom-onset prediction, the panel achieved an AUC of 0.870 compared with 0.676 for pTau217, a gain of about 29 percent.

Of particular clinical significance is the lead time the biomarkers appear to offer: circulating levels of the 34 circRNAs begin diverging from baseline roughly two to four years before cognitive symptoms manifest, a window that could allow earlier intervention, closer monitoring, or enrollment into disease-modifying drug trials while neurons remain comparatively intact. Circular Genomics, a company commercializing the underlying science, is now developing the panel into a diagnostic platform called CircPATH, positioning circulating RNA biomarkers as a potential successor to protein-based blood tests in Alzheimer's risk stratification.

trajectory

the path or course something follows over time

covalently closed loop transcript

a type of RNA molecule whose ends are joined together into a circle

overfitting

when a model matches the quirks of one dataset too closely to generalize to new data

phosphorylated

chemically modified by the addition of a phosphate group, often altering a protein's activity

endpoint

in a study, a specific outcome measured to judge success or effect

hazard ratio

a statistic comparing the rate at which an event occurs between two groups over time

disease-modifying

describing a treatment that alters the underlying course of a disease, not just its symptoms